Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Karbiener, M; Kindle, G; Meyts, I; Seppänen, MRJ; Candotti, F; Kamieniak, M; Ilk, R; Kreil, TR; Seidel, MG, , ESID‐COVID, Consortium.
Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency.
J Med Virol. 2024; 96(6):e29738 Doi: 10.1002/jmv.29738
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Seidel Markus
Study Group Members Med Uni Graz:: Hodl Isabel
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID-19). In addition to vaccination, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID-19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non-agammaglobulinemia patients on IGRT; 14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS-CoV-2 ("Wuhan" and Omicron strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious Omicron variants, an increase in case numbers was recorded that was comparable (~2- to 3-fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS-CoV-2 strain, yet only low levels of Omicron nAbs. Notably, shortly before the third (2022/2023) cold season, Omicron-neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID-19 cases dropped markedly. While a ~6-fold case reduction was recorded for the groups of non-agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30-fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID-19-protective effect of IGRT, at least for distinct groups of antibody-deficient patients.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Antibodies, Neutralizing - blood, immunology; Agammaglobulinemia - immunology, therapy; COVID-19 - immunology, therapy; Male - administration & dosage; SARS-CoV-2 - immunology; Female - administration & dosage; Adult - administration & dosage; Antibodies, Viral - blood, immunology, therapeutic use; Middle Aged - administration & dosage; Adolescent - administration & dosage; Aged - administration & dosage; Young Adult - administration & dosage; Child - administration & dosage; Child, Preschool - administration & dosage; Treatment Outcome - administration & dosage; Immunoglobulins - therapeutic use, immunology
Find related publications in this database (Keywords): agammaglobulinemia; COVID-19; intravenous immunoglobulin; neutralizing antibodies; primary immunodeficiency; SARS-CoV-2